Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Drug Manufacturers - Specialty & Generic

Healthcare
$4.78 +0.14%

+$0.01 today

Market cap
$791.33M
Beta
0.24
P/E (TTM)
5.6
EPS (TTM)
$0.63
52W Low $0.66High $5.78

Volume 2.22M

Average 2.35M

IRWD Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $106.51M rose 158.9% year over year, ahead of the +13.8% change in trailing-twelve-month revenue. Sequentially, it rose 123.2% from the prior quarter. Over 3 fiscal years it compounded at -10.3% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 2 analysts of $493.6M (+66.7%) for the fiscal year ending Dec 2026, a step up from the -15.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$106.51M+123.2% QoQ
Last fiscal yearDec 2025
$296.15M-15.7% YoY
LTMMar 2026
$361.51M+13.8% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+158.9%+34.7%-124.1 pp
1 year-15.7%+66.7%+82.4 pp
3-year CAGR-10.3%+20.9%+31.2 pp
5-year CAGR-18.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
296.15M USD
Year-over-year change
-15.7%
4-year CAGR
-8.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How IRWD compares with its peers on the latest reported figures

  • IRWD's LTM Mar 2026 revenue of $361.51M is the 2nd highest of the 3 companies compared; the peer median is $259.09M.
  • Its year-over-year change of +13.8% is the lowest of 2, against a peer median of +18.2%.
  • Over three fiscal years its annual growth of -10.3% compares with a peer median of +98.4%.
IRWD Competitors Peer median
Revenue for IRWD and competitors
Company Period LTM YoY 3-year CAGR
ARDXArdelyx, Inc.LTM Mar 2026$427.68M +18.2%+98.4%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$361.51M +13.8%-10.3%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$90.49M ——
Peer median (excluding IRWD) $259.09M+18.2%+98.4%

Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue413.75M410.6M442.74M351.41M296.15M
Cost of Revenue70.41M1.42M6.15M7.55M0
Gross Profit343.35M409.18M436.59M343.86M296.15M
Gross Margin83.0%99.7%98.6%97.9%100.0%
Research & Development70.41M44.27M116.09M111.42M95.14M
Selling, General & Admin0115.99M0082.26M
Operating Expenses111.09M158.84M1.38B250.73M177.39M
Depreciation & Amortization1.52M1.42M1.58M2.01M1.88M
EBITDA233.74M261.44M197.41M97.73M104.65M
EBITDA Margin56.5%63.7%44.6%27.8%35.3%
Operating Income232.26M250.34M(945.43M)93.12M118.76M
Operating Margin56.1%61.0%-213.5%26.5%40.1%
Interest Income726K9.5M18.97M4.47M4.08M
Interest Expense31.15M7.6M21.63M33.03M32.75M
Other Income / Expenses(31.6M)2.09M(2.64M)(27.93M)(48.73M)
Income Before Tax200.66M252.42M(948.07M)65.2M70.03M
Pre-Tax Margin48.5%61.5%-214.1%18.6%23.6%
Income Tax Expense(327.79M)77.36M83.49M64.32M46.01M
Net Income528.45M175.07M(1B)880K24.02M
Net Margin127.7%42.6%-226.4%0.3%8.1%
EPS (Basic)3.261.13(6.45)0.010.15
EPS (Diluted)3.210.96(6.45)0.010.15
Weighted Avg Shares162.25M154.37M155.44M159.08M162.22M
Weighted Avg Shares (Diluted)164.42M186.31M155.44M160.08M177.76M

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Intrinsic Alpha fair value

Locked

Current Price

$4.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.